Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
Open Access
- 4 October 2008
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1), 286
- https://doi.org/10.1186/1471-2407-8-286
Abstract
Elucidating the molecular mechanisms by which tumors become resistant to Herceptin is critical for the treatment of Her2-overexpressed metastatic breast cancer.Keywords
This publication has 34 references indexed in Scilit:
- Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 2006
- Herceptin: mechanisms of action and resistanceCancer Letters, 2005
- Intragenic ERBB2 kinase mutations in tumoursNature, 2004
- Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.Proceedings of the National Academy of Sciences, 1992
- Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogeneCell, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1987